A Retrospective Analysis Of The Efficacy Of RhTPO And Rhil-11 In The Treatment Of Chemotherapy-related Thrombocytopenia In Malignant Tumors And Its Effect On Patients' Quality Of Life

Objective:To investigate the effect of recombinant human thrombogenin(rhTPO)and recombinant human interleukin-11(rhIL-11)on chemotherapy-related thrombocytopenia in malignant tumors and the effect of the two drugs on the quality of life of patients.Methods:Retrospectively collected in October 2017 to May 2019 in our department?-?thrombocytopenia in the aftermath of the chemotherapy,74 patients with malignant tumor,according to different divided into treatment group A(rhTPO treatment group 39 cases)and group B(rhIL-11 treatment group 35 cases).Both groups were given drugs within 48h after chemotherapy.Group A was given rhTPO 300U/kg subcutaneously once per day.Group B was given rhIL-11 1.5mg subcutaneously once per day.When the PLT reaches to 100×10~9/L the drug is stopped.To compare Platelet recovery time between the two groups;compare the effectiveness of using the two drugs;Platelet levels before and after treatment were compared between the two groups.Platelet infusion rate was compared between the two groups.The quality of life scores of the two groups were compared after 7-14 days.The incidence and severity of adverse reactions were compared between the two groups.Results:The time taken for platelets in group A to rise to 50×10~9/L,75×10~9/L,and 100×10~9/L were all less than those in group B,with statistically significant differences(P<0.05).The total effective rate of group A was significantly higher than that of group B,and the difference was statistically significant(P<0.05).There was no significant difference in the baseline platelet values between the two groups before treatment(P>0.05),and the platelet levels in the two groups after treatment were significantly higher than before treatment(P<0.01),with statistically significant differences.After treatment,the platelet level in group A was higher than that in group B,and the difference was statistically significant(P>0.05).Three patients in group A received platelet infusion(7.7%),and five patients in group B received platelet infusion(14.2%),with no difference between the groups(P>0.05).The incidence of adverse reactions was 12.8%in group A and 34.3%in group B.There were significant differences between the groups of adverse reactions(P<0.05).The adverse reactions of the two groups improved after symptomatic treatment.The severity of adverse drug reactions in group A was slightly higher than that in group B.Group A scored better than group B in the dimensions of general health(QL),physiology(PF),role(RF),pain(PA),fatigue(FA)and dyspnea(DY),with significant differences(P<0.05).Social(SF),emotional(EF),cognitive(CF),nausea and vomiting(NV),sleep disorder(SL),loss of appetite(AP),diarrhea(DI),constipation(CO),and perception of economic difficulties(FI)were not significantly different between the two groups(P>.05).Conclusion:rhTPO is effective and safe in the treatment of tumor chemotherapy-related thrombocytopenia,may improve the quality of life of patients with grade III-IV thrombocytopenia after chemotherapy.